IN2014KN02583A - - Google Patents
Info
- Publication number
- IN2014KN02583A IN2014KN02583A IN2583KON2014A IN2014KN02583A IN 2014KN02583 A IN2014KN02583 A IN 2014KN02583A IN 2583KON2014 A IN2583KON2014 A IN 2583KON2014A IN 2014KN02583 A IN2014KN02583 A IN 2014KN02583A
- Authority
- IN
- India
- Prior art keywords
- hpps
- render
- parent
- hpcs
- drugs
- Prior art date
Links
- 206010049933 Hypophosphatasia Diseases 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 3
- 229940079593 drug Drugs 0.000 abstract 3
- 238000011282 treatment Methods 0.000 abstract 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 abstract 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 230000035515 penetration Effects 0.000 abstract 2
- 208000006673 asthma Diseases 0.000 abstract 1
- 230000004888 barrier function Effects 0.000 abstract 1
- 239000002359 drug metabolite Substances 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 230000002685 pulmonary effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/625—Salicylic acid; Derivatives thereof having heterocyclic substituents, e.g. 4-salicycloylmorpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- G—PHYSICS
- G05—CONTROLLING; REGULATING
- G05B—CONTROL OR REGULATING SYSTEMS IN GENERAL; FUNCTIONAL ELEMENTS OF SUCH SYSTEMS; MONITORING OR TESTING ARRANGEMENTS FOR SUCH SYSTEMS OR ELEMENTS
- G05B19/00—Programme-control systems
- G05B19/02—Programme-control systems electric
- G05B19/18—Numerical control [NC], i.e. automatically operating machines, in particular machine tools, e.g. in a manufacturing environment, so as to execute positioning, movement or co-ordinated operations by means of programme data in numerical form
- G05B19/409—Numerical control [NC], i.e. automatically operating machines, in particular machine tools, e.g. in a manufacturing environment, so as to execute positioning, movement or co-ordinated operations by means of programme data in numerical form characterised by using manual data input [MDI] or by using control panel, e.g. controlling functions with the panel; characterised by control panel details or by setting parameters
-
- G—PHYSICS
- G05—CONTROLLING; REGULATING
- G05B—CONTROL OR REGULATING SYSTEMS IN GENERAL; FUNCTIONAL ELEMENTS OF SUCH SYSTEMS; MONITORING OR TESTING ARRANGEMENTS FOR SUCH SYSTEMS OR ELEMENTS
- G05B2219/00—Program-control systems
- G05B2219/30—Nc systems
- G05B2219/33—Director till display
- G05B2219/33192—Radio link, wireless
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Manufacturing & Machinery (AREA)
- Physics & Mathematics (AREA)
- Otolaryngology (AREA)
- Automation & Control Theory (AREA)
- General Physics & Mathematics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Human Computer Interaction (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210151555 | 2012-01-18 | ||
PCT/CN2013/072693 WO2013170655A1 (en) | 2012-01-18 | 2013-03-15 | High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014KN02583A true IN2014KN02583A (nl) | 2015-05-08 |
Family
ID=49583088
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN2583KON2014 IN2014KN02583A (nl) | 2012-01-18 | 2013-03-15 |
Country Status (17)
Country | Link |
---|---|
US (4) | US11857545B2 (nl) |
EP (2) | EP2849738B1 (nl) |
JP (2) | JP6445967B2 (nl) |
KR (5) | KR20220130239A (nl) |
CN (4) | CN107929743B (nl) |
AU (2) | AU2013262320B2 (nl) |
BR (1) | BR112014028643A8 (nl) |
CA (2) | CA2872121C (nl) |
ES (1) | ES2969344T3 (nl) |
HK (3) | HK1207562A1 (nl) |
IN (1) | IN2014KN02583A (nl) |
MX (1) | MX2014013910A (nl) |
PL (1) | PL2849738T3 (nl) |
RU (1) | RU2683934C2 (nl) |
TW (1) | TWI658836B (nl) |
WO (1) | WO2013170655A1 (nl) |
ZA (1) | ZA201407777B (nl) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT3104854T (pt) | 2014-02-10 | 2020-06-26 | Respivant Sciences Gmbh | Estabilizadores de mastócitos para tratamento de doença pulmonar |
AU2015213678C1 (en) | 2014-02-10 | 2019-03-21 | Respivant Sciences Gmbh | Mast cell stabilizers treatment for systemic disorders |
NO2723977T3 (nl) * | 2014-03-19 | 2018-03-10 | ||
WO2017027402A1 (en) | 2015-08-07 | 2017-02-16 | Patara Pharma, LLC | Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders |
WO2017027387A1 (en) | 2015-08-07 | 2017-02-16 | Patara Pharma, LLC | Methods for the treatment of mast cell related disorders with mast cell stabilizers |
CN110139646A (zh) | 2016-08-31 | 2019-08-16 | 瑞思皮万特科学有限责任公司 | 用于治疗由特发性肺纤维化引起的慢性咳嗽的色甘酸组合物 |
JP2019531308A (ja) | 2016-10-07 | 2019-10-31 | レシュピファント サイエンシス ゲゼルシャフト ミット ベシュレンクター ハフトゥングRespivant Sciences Gmbh | 肺線維症の治療のためのクロモリン組成物 |
WO2019216360A1 (ja) * | 2018-05-10 | 2019-11-14 | 学校法人 慶應義塾 | 前立腺がんの予防又は治療剤 |
JP2022500437A (ja) | 2018-09-14 | 2022-01-04 | ジャンイン ユスン ファーマシューティカル カンパニー,リミテッド | モンテルカストおよびペプチドの新規接合体 |
WO2021175250A1 (en) * | 2020-03-03 | 2021-09-10 | Aptorum Therapeutics Limited | Compounds and methods for treating diseases and/or conditions caused by coronavirus |
US11116737B1 (en) | 2020-04-10 | 2021-09-14 | University Of Georgia Research Foundation, Inc. | Methods of using probenecid for treatment of coronavirus infections |
CN113933401B (zh) * | 2020-06-29 | 2023-07-21 | 重庆华邦制药有限公司 | 分离检测阿伐斯汀中间体z3中基因毒性杂质的方法 |
CN114409673B (zh) * | 2022-01-04 | 2023-08-08 | 广东克冠达医药科技有限公司 | 一种***喃类化合物及其制备方法与应用 |
WO2023134733A1 (en) * | 2022-01-17 | 2023-07-20 | Techfields Pharma Co., Ltd. | Treatment of signs, symptoms and/or complications of viral, bacterial, protozoal, and/or fungal infections by high penetration prodrugs |
Family Cites Families (125)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB100208A (en) | 1915-03-24 | 1917-03-01 | Isidore Swientoslawsk Morrison | Improvements in Watch Movements. |
US2694031A (en) | 1949-07-07 | 1954-11-09 | Leo Pharm Prod Ltd | Hydroiodides of amino esters of penicillin and oil composition thereof |
US2694061A (en) | 1949-07-07 | 1954-11-09 | Leo Pharm Prod Ltd | Method of producing aminoalcohol esters of penicillin |
US2694063A (en) | 1949-07-07 | 1954-11-09 | Leo Pharm Prod Ltd | Quaternary ammonium addition salts of penicillin esters |
US2671805A (en) | 1952-07-02 | 1954-03-09 | Searle & Co | Basically substituted o-arylamino-benzamides |
GB759603A (en) | 1952-07-10 | 1956-10-24 | Yvan Villax | Method for the production of esters of penicillin |
GB768347A (en) | 1953-02-06 | 1957-02-13 | Knud Abildgaard | Sulphanilate salts of amino alcohol esters of penicillin |
GB984471A (en) | 1961-01-12 | 1965-02-24 | Parke Davis & Co | Anthranilic acid esters and methods for producing the same |
CH399486A (fr) | 1962-10-02 | 1965-09-30 | Biosedra Lab | Procédé de préparation de nouvelles salicylamides |
US3365483A (en) | 1963-06-05 | 1968-01-23 | Starogardzkie Zakl Farma | Process for obtaining diethylaminoethanol acetylsalicylate hydrochloride |
US3420871A (en) | 1964-09-01 | 1969-01-07 | Parke Davis & Co | Anthranilic acid esters |
FR5342M (nl) | 1966-03-08 | 1967-09-04 | ||
DK121236B (da) | 1967-07-03 | 1971-09-27 | Gea As | Analogifremgangsmåde til fremstilling af terapeutisk aktive, basisk substituerede amider af N-substituerede antranilsyrer, eller syreadditionssalte deraf. |
GB1187259A (en) | 1967-10-23 | 1970-04-08 | Hexachimie | New Aminoalkyl Esters of 2-Anilino-Nicotinic Acids and process for their manufacture |
US3956363A (en) | 1969-08-08 | 1976-05-11 | Merck & Co., Inc. | Substituted indenyl acetic acids |
US3957764A (en) | 1969-11-11 | 1976-05-18 | Lovens Kemiske Fabrik Produktionsaktieselskab | 6-aminopenicillanic acid derivatives |
CA996929A (en) | 1971-04-05 | 1976-09-14 | Kohzi Nakano | Acyloxyalkyl ester derivatives of penicillin |
GB1335317A (en) | 1971-06-23 | 1973-10-24 | Leo Pharm Prod Ltd | Cephalosporin esters salts thereof and methods for their pre paration |
US3966923A (en) | 1972-06-05 | 1976-06-29 | Pierre Fabre S.A. | Medicaments intended for the prevention and treatment of ischemic disturbances |
US4006181A (en) | 1972-07-27 | 1977-02-01 | Pierre Fabre S.A. | Process for the obtaining of esters of acetylsalicylic acid and amino alcohols |
US3914811A (en) | 1972-07-31 | 1975-10-28 | Jonathan Francis | Lightweight, compact air mattress with improved casing and inflatable members |
ES428213A1 (es) | 1974-07-12 | 1976-07-16 | Andreu Sa Dr | Procedimiento para la obtencion de esteres dialquilaminoal-quilicos de penicilina. |
US4012508A (en) | 1975-02-03 | 1977-03-15 | Burton Verna M | Topical composition and method |
FR2348701A1 (fr) | 1976-04-22 | 1977-11-18 | Hexachimie | Nouveau derive du p-acetamidophenol,sa preparation et son utilisation en therapeutique |
US4150157A (en) | 1976-06-11 | 1979-04-17 | Beecham Group Limited | Penicillin compositions |
US4215120A (en) | 1977-07-14 | 1980-07-29 | Beecham Group Limited | Penicillin esters and their preparation |
AU518216B2 (en) | 1977-09-06 | 1981-09-17 | Hafslund Nycomed Pharma Aktiengesellschaft | Thienothiazine derivatives |
US4206220A (en) | 1978-07-13 | 1980-06-03 | Interx Research Corporation | Prodrugs for the improved delivery of non-steroidal anti-inflammatory agents |
US4244948A (en) | 1979-05-07 | 1981-01-13 | Allergan Pharmaceuticals, Inc. | Medical use of esters of acetylsalicylic acid to treat acne |
IN153407B (nl) | 1979-09-28 | 1984-07-14 | Ciba Geigy Ag | |
DE3023206A1 (de) | 1979-11-02 | 1982-01-14 | Efeka Friedrich & Kaufmann GmbH & Co KG, 3000 Hannover | Indometacin-ester, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
JPS57183738A (en) | 1981-05-06 | 1982-11-12 | Yamanouchi Pharmaceut Co Ltd | Aromatic carboxylic acid derivative |
JPS5852291A (ja) | 1981-09-22 | 1983-03-28 | Kureha Chem Ind Co Ltd | ペニシリン系抗生物質誘導体とその医薬剤 |
FR2542998B1 (fr) | 1983-03-24 | 1986-01-31 | Rhone Poulenc Sante | Nouvelle forme transdermale du dinitrate d'isosorbide |
US4640689A (en) | 1983-08-18 | 1987-02-03 | Drug Delivery Systems Inc. | Transdermal drug applicator and electrodes therefor |
DE3347128A1 (de) | 1983-12-22 | 1985-07-11 | Schering AG, 1000 Berlin und 4709 Bergkamen | 9-halogen-(delta)(pfeil hoch)2(pfeil hoch)-prostaglandinderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
EP0152379A3 (de) | 1984-02-15 | 1986-10-29 | Ciba-Geigy Ag | Verfahren zur Herstellung von pharmazeutischen Zusammensetzungen enthaltend unilamellare Liposomen |
GB2157284B (en) | 1984-04-11 | 1987-11-04 | Leo Pharm Prod Ltd | 6-b-halopenicillanic acid salts |
GB8511988D0 (en) | 1985-05-11 | 1985-06-19 | Beecham Group Plc | Compounds |
US4822773A (en) | 1985-06-28 | 1989-04-18 | Merck & Co., Inc. | Enhancement of absorption of drugs from gastrointestinal tract using choline ester salts |
IT1213579B (it) | 1986-07-03 | 1989-12-20 | Angelo Signor Marino Nicolini | Flogistica. esteri di salsalato con guaiacolo atti al trattamento di broncopneumapatie a base |
JPS6452742A (en) | 1987-04-27 | 1989-02-28 | Syntex Pharma Int | Omega-quaternary ammonium alkyl ester and thioester of acidic non-steroidal antiinflammatory |
US5321020A (en) | 1989-03-28 | 1994-06-14 | Pfizer Inc. | Antibacterial 2-carbapenem derivatives |
JP2672363B2 (ja) | 1989-03-29 | 1997-11-05 | 帝人株式会社 | 有機非線形光学材料 |
US5760261A (en) | 1990-02-28 | 1998-06-02 | Guttag; Alvin | Higher fatty acid derivatives of salicylic acid and salts thereof |
US5109011A (en) | 1990-07-30 | 1992-04-28 | Hoechst-Roussel Pharmaceuticals Incorporated | P-acylaminophenoxycarbamates and derivatives |
CZ85994A3 (en) | 1991-10-16 | 1994-12-15 | Richardson Vicks Inc | Pharmaceutical preparation for local use and exhibiting increased penetration through skin |
HRP921157A2 (en) | 1991-12-20 | 1994-10-31 | Lohmann Therapie Syst Lts | Transdermal system of applying acetilsalicilyc acid in antithrombosys therapy |
US5629019A (en) | 1992-02-27 | 1997-05-13 | Alza Corporation | Formulations with hydrophobic permeation enhancers |
US5190953A (en) | 1992-03-26 | 1993-03-02 | A. H. Robins Company, Incorporated | Heterocyclic carboxylic acid amides and esters of azabicyclic compounds as gastric prokinetic, antiemetic, anxiolytic and antiarrhythmic agents |
US5300512A (en) | 1992-06-24 | 1994-04-05 | G. D. Searle & Co. | Benzimidazole compounds |
AU5342894A (en) | 1992-10-30 | 1994-05-24 | Merck Sharp & Dohme Limited | Tachykinin antagonists |
US5399562A (en) | 1994-02-04 | 1995-03-21 | G. D. Searle & Co. | Indolones useful as serotonergic agents |
GB9404756D0 (en) | 1994-03-11 | 1994-04-27 | Knx Limited | Data output control |
WO1995034813A1 (en) | 1994-06-14 | 1995-12-21 | Smithkline Beecham Corporation | Resins for solid state synthesis |
US5626838A (en) | 1995-03-13 | 1997-05-06 | The Procter & Gamble Company | Use of ketorolac for treatment of squamous cell carcinomas of the oral cavity or oropharynx |
US5654337A (en) | 1995-03-24 | 1997-08-05 | II William Scott Snyder | Topical formulation for local delivery of a pharmaceutically active agent |
AUPN531195A0 (en) | 1995-09-11 | 1995-10-05 | J.W. Broadbent Nominees Pty. Ltd. | Lipid extract having anti-inflamatory activity |
US5570559A (en) | 1995-09-26 | 1996-11-05 | Lewis; Thomas D. | Fall arrestor |
US5929086A (en) | 1996-05-10 | 1999-07-27 | Pharmacia & Upjohn Company | Topical administration of antimicrobial agents for the treatment of systemic bacterial diseases |
DK0898477T3 (da) | 1996-05-10 | 2003-03-24 | Upjohn Co | Topisk indgivelse af prenafloxcin til behandlingen af systemiske bakterielle sygdomme |
IT1282736B1 (it) | 1996-05-21 | 1998-03-31 | Angelini Ricerche Spa | Uso di derivati del p-amminofenolo per preparare composizioni farmaceutiche utili nel trattamento di malattie neurodegenerative |
KR100213465B1 (ko) | 1996-11-01 | 1999-08-02 | 최좌진 | 케토프로펜 패취 조성물 |
US6011049A (en) | 1997-02-19 | 2000-01-04 | Warner-Lambert Company | Combinations for diabetes |
EP1642575B1 (en) | 1997-03-10 | 2009-10-28 | Loma Linda University Medical Center | Use of r-carprofen for the prevention of alzheimer's disease |
US6451815B1 (en) | 1997-08-14 | 2002-09-17 | Aventis Pharmaceuticals Inc. | Method of enhancing bioavailability of fexofenadine and its derivatives |
US5885597A (en) | 1997-10-01 | 1999-03-23 | Medical Research Industries,Inc. | Topical composition for the relief of pain |
IL137518A0 (en) | 1998-01-29 | 2001-07-24 | Bristol Myers Squibb Co | Derivatives of 1,2,4-oxadiazolone |
EP1094781B1 (en) | 1998-07-07 | 2008-07-02 | Transdermal Technologies Inc. | Compositions for rapid and non-irritating transdermal delivery of pharmaceutically active agents and methods for formulating such compositions and delivery thereof |
US20030087962A1 (en) | 1998-10-20 | 2003-05-08 | Omeros Corporation | Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation |
SE9900941D0 (sv) | 1998-12-23 | 1999-03-16 | Nomet Management Serv Bv | Novel retinoic acid derivatives and their use |
AU4841700A (en) | 1999-05-12 | 2000-11-21 | Nitromed, Inc. | Nitrosated and nitrosylated potassium channel activators, compositions and methods of use |
US6368618B1 (en) | 1999-07-01 | 2002-04-09 | The University Of Georgia Research Foundation, Inc. | Composition and method for enhanced transdermal absorption of nonsteroidal anti-inflammatory drugs |
US6669951B2 (en) | 1999-08-24 | 2003-12-30 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into epithelial tissues |
AU3104301A (en) | 2000-01-20 | 2001-07-31 | Noven Pharmaceuticals, Inc. | Compositions and methods to effect the release profile in the transdermal administration of active agents |
US6429223B1 (en) | 2000-06-23 | 2002-08-06 | Medinox, Inc. | Modified forms of pharmacologically active agents and uses therefor |
DE10034802A1 (de) | 2000-07-18 | 2002-01-31 | Bayer Ag | Stabile Salze von O-Acetylsalicylsäure mit basischen Aminosäuren |
US6416772B1 (en) | 2001-01-12 | 2002-07-09 | H. Wayne Van Engelen | Topical dermal anaesthetic |
US6528040B1 (en) | 2001-01-18 | 2003-03-04 | Maurine Pearson | EMU oil-based formulations for use as an analgesic, anesthetic and antipruritic |
ITMI20010395A1 (it) | 2001-02-27 | 2002-08-27 | Dompe Spa | Omega-amminoalchilammidi di acidi r-2-aril-propionici come inibitori della chemiotassi di cellule polimorfonucleate e mononucleate |
WO2003022270A1 (en) | 2001-09-13 | 2003-03-20 | Noven Pharmaceuticals, Inc. | Transdermal administration of an enalapril ester |
JP2005529840A (ja) | 2001-10-16 | 2005-10-06 | ヒプニオン, インコーポレイテッド | Cns標的モジュレータを使用するcns障害の治療 |
US20030143165A1 (en) | 2002-01-25 | 2003-07-31 | Allan Evans | NSAID-containing topical formulations that demonstrate chemopreventive activity |
ITMI20021399A1 (it) | 2002-06-25 | 2003-12-29 | Nicox Sa | Inibitori della cicloossigenasi 2 |
AU2002347747A1 (en) | 2002-07-23 | 2004-02-09 | Ardenia Investments Ltd. | Retinol derivatives, their use in the treatment of cancer and for potentiating the efficacy of other cytotoxic agents |
EP1534340B1 (en) | 2002-09-06 | 2011-11-16 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto |
RU2332425C2 (ru) * | 2002-09-06 | 2008-08-27 | Инсёрт Терапьютикс, Инк. | Полимеры на основе циклодекстрина для доставки терапевтических средств |
US20040109826A1 (en) * | 2002-12-06 | 2004-06-10 | Dey, L.P. | Stabilized albuterol compositions and method of preparation thereof |
ZA200507284B (en) | 2003-03-12 | 2007-03-28 | Celgene Corp | 7-amino-isoindolyl compounds and their pharmaceutical uses |
US7052715B2 (en) | 2003-04-11 | 2006-05-30 | All Natural Fmg, Inc. | Alcohol-free transdermal analgesic composition and processes for manufacture and use thereof |
CA2528975A1 (en) | 2003-06-10 | 2004-12-16 | Pfizer Inc. | Therapeutic combinations comprising pde inhibitors and vasopressin receptor antagonists for the treatment of dysmenorrhoea |
SG178721A1 (en) | 2003-07-29 | 2012-03-29 | Signature R & D Holdings Llc | Amino acid prodrugs |
US8173840B2 (en) | 2003-07-29 | 2012-05-08 | Signature R&D Holdings, Llc | Compounds with high therapeutic index |
DE10335726A1 (de) | 2003-08-05 | 2005-03-03 | Bayer Cropscience Gmbh | Verwendung von Hydroxyaromaten als Safener |
WO2005030331A1 (en) | 2003-09-26 | 2005-04-07 | Fairfield Clinical Trials, Llc | Combination antihistamine medication |
US7186744B2 (en) | 2003-11-13 | 2007-03-06 | Allergan, Inc. | Prostamides for the treatment of glaucoma and related diseases |
CA2562219A1 (en) | 2004-04-05 | 2005-10-20 | Laboratorios Del Dr. Esteve, S.A. | Active substance combination comprising a carbinol combined to at least an nsaid |
DE102004025324A1 (de) | 2004-05-19 | 2005-12-08 | Boehringer Ingelheim Vetmedica Gmbh | Flüssige Zubereitung für die Veterinärmedizin, Verfahren zu deren Herstellung und deren Verwendung |
TWI276687B (en) | 2004-06-30 | 2007-03-21 | Univ Nat Cheng Kung | Method for kinetic resolution of alpha-substituted acids and esters thereof by using papaya lipases |
JP2008120684A (ja) | 2005-03-07 | 2008-05-29 | Kumamoto Univ | 抗アレルギー薬 |
JP2008533174A (ja) | 2005-03-16 | 2008-08-21 | エラン ファーマ インターナショナル リミテッド | ナノ粒子ロイコトリエン受容体拮抗薬/副腎皮質ステロイド製剤 |
US20060222692A1 (en) | 2005-03-31 | 2006-10-05 | Fairfield Clinical Trials Llc | Method and compositions for transdermal administration of antimicrobial medications |
BRPI0609802A2 (pt) | 2005-05-20 | 2017-05-02 | Alantos Pharmaceuticals Holding Inc | composto, composição farmacêutica e uso de um composto |
CN100500149C (zh) * | 2005-06-22 | 2009-06-17 | 晟德大药厂股份有限公司 | 白三烯素拮抗剂口服液组成 |
AU2006346195B2 (en) | 2006-07-09 | 2013-03-07 | Techfields Biochem Co. Ltd | Positively charged water-soluble prodrugs of aspirin |
DK2041068T3 (en) | 2006-07-18 | 2017-02-27 | Techfields Biochem Co Ltd | POSITIVELY CHARGED, WATER SOLUBLE PRODRUGS OF IBUPROFEN WITH VERY FAST SKIN PENETRATION SPEED |
PL2046727T3 (pl) | 2006-07-25 | 2014-08-29 | Techfields Biochem Co Ltd | Dodatnio naładowane rozpuszczalne w wodzie proleki diklofenaku o bardzo szybkim stopniu przenikania przez skórę |
CN101500983B (zh) | 2006-07-26 | 2015-09-16 | 于崇曦 | 具有快速皮肤穿透速度的带正电荷的水溶性二氟尼柳及相关化合物的前药 |
EP2049482B1 (en) | 2006-08-08 | 2015-10-21 | Techfields Biochem Co. Ltd | Positively charged water-soluble prodrugs of aryl- and heteroarylacetic acids with very fast skin penetration rate |
US8458932B2 (en) | 2006-08-11 | 2013-06-11 | Alameda Technology, Llc | Optical illusion device |
EP2054384A4 (en) | 2006-08-15 | 2010-11-03 | Techfields Biochem Co Ltd | POSITIVELY LOADED WATER-SOLUBLE PRODRUGS OF ARYL AND HETEROARYLPROPIONIC ACIDS WITH A VERY FAST SKIN PUNCHING RATE |
JP5183478B2 (ja) | 2006-08-31 | 2013-04-17 | ナノキャリア株式会社 | 活性成分内包ポリマーミセル含有経皮組成物、経皮医薬品組成物および経皮化粧品組成物 |
PL2084132T3 (pl) * | 2006-09-03 | 2019-03-29 | Techfields Biochem Co. Ltd | Dodatnio naładowane rozpuszczalne w wodzie proleki z kwasów n-arylantranilowych z bardzo szybką penetracją skóry |
JP5466006B2 (ja) | 2006-09-03 | 2014-04-09 | テックフィールズ バイオケム カンパニー リミテッド | 非常に速い皮膚浸透率を有するアセトアミノフェン及び関連化合物の正荷電水溶性プロドラッグ |
AU2006349143B2 (en) | 2006-10-02 | 2013-07-18 | Techfields Biochem Co. Ltd | Positively charged water-soluble prodrugs of prostaglandins and related compounds with very high skin penetration rates |
CN101511774B (zh) | 2006-10-03 | 2015-05-13 | 于崇曦 | 具有快速皮肤穿透速度的带正电荷的水溶性的芥子气类化合物及其相关化合物的前药 |
CN101522692A (zh) | 2006-10-11 | 2009-09-02 | 于崇曦 | 具有快速皮肤穿透速度的带正电荷的水溶性的昔康及其相关化合物的前药 |
EP2656879B1 (en) * | 2006-12-10 | 2017-06-28 | Chongxi Yu | Transdermal delivery systems of beta-lactam antibiotics |
PL2115140T3 (pl) * | 2007-01-31 | 2017-03-31 | Yu | Dodatnio naładowane rozpuszczalne w wodzie proleki 1H-imidazo[4,5-c]chinolino-4-amin i powiązane związki o bardzo wysokich wskaźnikach penetracji przez skórę |
CA2691446C (en) * | 2007-06-04 | 2021-07-06 | Techfields Inc | Pro-drugs of nsaias with very high skin and membranes penetration rates and their new medicinal uses |
WO2009122187A2 (en) * | 2008-04-03 | 2009-10-08 | Cipla Limited | Pharmaceutical composition |
EP2370406A4 (en) * | 2008-12-04 | 2014-02-19 | Chongxi Yu | COMPOSITIONS WITH HIGH PENETRATION AND ITS APPLICATIONS |
US8084896B2 (en) | 2008-12-31 | 2011-12-27 | Electro Scientific Industries, Inc. | Monolithic stage positioning system and method |
WO2010142241A1 (en) * | 2009-06-10 | 2010-12-16 | Techfields Biochem Co., Ltd. | High penetration compositions or prodrugs of antimicrobials and antimicrobial-related compounds |
TWI496577B (zh) * | 2010-06-10 | 2015-08-21 | Shanghai Techfields Biochem Co Ltd | 抗菌劑和抗菌劑相關化合物的高滲透性前藥組合物 |
-
2013
- 2013-03-15 JP JP2015511907A patent/JP6445967B2/ja active Active
- 2013-03-15 KR KR1020227031100A patent/KR20220130239A/ko not_active IP Right Cessation
- 2013-03-15 CN CN201711440275.7A patent/CN107929743B/zh active Active
- 2013-03-15 MX MX2014013910A patent/MX2014013910A/es unknown
- 2013-03-15 KR KR1020217008219A patent/KR102332837B1/ko active IP Right Grant
- 2013-03-15 RU RU2014150779A patent/RU2683934C2/ru not_active IP Right Cessation
- 2013-03-15 KR KR1020147034771A patent/KR102309973B1/ko active IP Right Grant
- 2013-03-15 KR KR1020217038444A patent/KR102443057B1/ko active IP Right Grant
- 2013-03-15 BR BR112014028643A patent/BR112014028643A8/pt not_active Application Discontinuation
- 2013-03-15 PL PL13791142.6T patent/PL2849738T3/pl unknown
- 2013-03-15 IN IN2583KON2014 patent/IN2014KN02583A/en unknown
- 2013-03-15 WO PCT/CN2013/072693 patent/WO2013170655A1/en active Application Filing
- 2013-03-15 EP EP13791142.6A patent/EP2849738B1/en active Active
- 2013-03-15 CA CA2872121A patent/CA2872121C/en active Active
- 2013-03-15 CN CN202310350740.7A patent/CN116898848A/zh active Pending
- 2013-03-15 ES ES13791142T patent/ES2969344T3/es active Active
- 2013-03-15 AU AU2013262320A patent/AU2013262320B2/en not_active Ceased
- 2013-03-15 KR KR1020207010004A patent/KR102232625B1/ko active IP Right Grant
- 2013-03-15 EP EP23214406.3A patent/EP4356912A2/en active Pending
- 2013-03-15 CN CN201380025658.1A patent/CN104540504A/zh active Pending
- 2013-03-15 CA CA3189252A patent/CA3189252A1/en active Pending
- 2013-03-15 CN CN201910623927.3A patent/CN111012914A/zh active Pending
- 2013-05-15 TW TW102117286A patent/TWI658836B/zh active
-
2014
- 2014-10-24 ZA ZA2014/07777A patent/ZA201407777B/en unknown
- 2014-11-14 US US14/542,486 patent/US11857545B2/en active Active
-
2015
- 2015-08-24 HK HK15108154.8A patent/HK1207562A1/xx unknown
- 2015-09-25 HK HK15109463.2A patent/HK1208633A1/xx unknown
-
2018
- 2018-05-22 AU AU2018203612A patent/AU2018203612A1/en not_active Abandoned
- 2018-10-17 HK HK18113294.6A patent/HK1254324A1/zh unknown
- 2018-11-30 JP JP2018225104A patent/JP7235487B2/ja active Active
-
2019
- 2019-01-16 US US16/248,842 patent/US11813256B2/en active Active
-
2023
- 2023-11-13 US US18/507,797 patent/US20240115562A1/en active Pending
- 2023-12-29 US US18/400,716 patent/US20240226084A9/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014KN02583A (nl) | ||
MX2015012559A (es) | Novedosos fármacos de alta penetración y sus composiciones para el tratamiento de enfermedades de parkinson. | |
CY1123476T1 (el) | Τροποποιητες πυρηνικης μεταφορας και χρησεις αυτων | |
MX2021000588A (es) | Composiciones de alta penetracion y sus aplicaciones. | |
MX2020007485A (es) | Compuestos antiproliferativos y metodos de uso de los mismos. | |
MX2023000320A (es) | Metodos para modular los niveles de farmaco en plasma mediante el uso de eritrohidroxibupropion. | |
WO2014205389A8 (en) | Nuclear transport modulators and uses thereof | |
MX2020009780A (es) | Compuestos de inhibidor de autotaxina. | |
MX2013006040A (es) | Antagonistas del receptor de acido lisofosfatidico y su uso en el tratamiento de fibrosis. | |
MX368903B (es) | Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas. | |
IN2015DN03826A (nl) | ||
MX338552B (es) | Composiciones o pro-farmacos de alta penetracion de compuestos antimicrobianos o relacionados a los antimicrobianos. | |
MX2016006688A (es) | Inhibidores tetraciclicos de autotaxina. | |
WO2016100949A3 (en) | Method and compositions for dissolving or solubilizing therapeutic agents | |
PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
MX2015009891A (es) | Composiciones farmaceuticas que comprenden particulas cristalinas de multicomponentes adecuadas para usar en terapia de inhalacion. | |
BR102012028120B8 (pt) | Uso de um ou mais derivados de ingenol, composição farmacêutica e medicamento | |
TN2016000497A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
MX2019001210A (es) | Composicion farmaceutica anticancer. | |
BR112017012975A2 (pt) | formulações injetáveis de paracetamol | |
PH12020500472A1 (en) | Autotaxin inhibitor compounds | |
IN2013MU01252A (nl) | ||
MX2011011881A (es) | Uso de la delfinidina y sus derivados para preparar un medicamento para el tratamiento de la prediabetes y diabetes. | |
WO2016164719A3 (en) | Methods used to treat cancer | |
TH161822A (th) | การบำบัดซีบอเรีย |